We Are CompassX.
We help our clients through their most challenging initiatives and deliver results that extend the value of their investments. We are a consulting firm based in Southern California specializing in regulated industries like healthcare, life sciences, and financial services. Our exceptional, locally-resourced team partners with our clients to offer a superior customer experience by acting as an extension of their organizations.
If you are ready. We invite you to join us.
Is your company lucky enough to employ one of the most respected CEOs in the world? Barron's Magazine released their 11th annual list of top corporate bosses; here I narrow the list to only leaders in the Health and Life Science industry. 1). Joseph Jimenez, Novartis CEO since 2010Annualized Returns While CEO -- 17%Market Value -- $277 billionProfile - A relative rookie in the Life Science world, Jimenez only joined Novartis in 2007. Prior, he ran North American operations for H.J. Heinz,...26 - March - 2015
Last year I authored this statement, “The FDA has undergone transformations in the past several years in hopes of making it a more efficient regulatory body.” A year later and with the agency’s annual 2014 results published, we see yet more positive trends. Last year the FDA’s Center for Drug Evaluation and Research (CDER) approved 41 new molecular entities and biologics—well above their decade average of 25 approvals. (1) This doesn’t mean the FDA can stop moving forward. In one of...19 - February - 2015
The premier study on drug development costs was released and the results will astonish—costs have increased by 145% in the past decade (1). In 2003 the Tufts Center for the Study of Drug Development released what has become the financial benchmark for comparing drug development costs. In 2003 the average cost was estimated to be $800 million. The new cost--$2.6 billion. But I'll explain below, why consumers are actually getting a great deal on what they pay at the pharmacy for...24 - January - 2015
2014 has concluded and it was very kind to the portfolios of Health and Life Science executives. As of today, the Dow Jones U.S. Healthcare broad industry index returned 25% (second only to Utilities +26%) during 2014. Healthcare was tops during the past three years, with annualized returns of +27%. The Dow Jones U.S. Healthcare index includes: Providers, Equipment, Supplies, Biotech and Pharma (1). The companies featured in my blog have done even better, returning on average +82% this year....05 - January - 2015
It was the year 2014... The World Health Organization (WHO) issues this frightening statement, "In a post-antibiotic era in which common infections and minor injuries can kill - far from being an apocalyptic fantasy, is instead a very real possibility for the 21st Century." Drug development slows. The approval of antibiotics and antivirals have been been cut by two-thirds during the period from 1980 to 2009. Infectious disease experts maintain overuse has...31 - October - 2014
A new study presented at the Animal Behavior Society Conference categorizes wolves *not* dogs as the more tolerant, cooperative and independent thinking of the species. The theory and supporting data presented goes on to explain that we have bred and trained dogs into a hierarchal, obedient species. Our four-legged friends have become ever more reliant on us, their human pack leaders. Two separate tests were conducted, both studies were evenly...04 - October - 2014